Search results for: 'biologics contract development'

27 Oct 2021  |  Asia Pacific  |  Frost Radar

Frost Radar™ for Economic Development: Broader Asia, 2021

Australia, South Korea, and New Zealand Emerge as the Broader Asian Leaders

Infographics

×

Key Issues Addressed

The Frost Radar™ for Economic Development determines a region's future growth and development potential measured by its ability to enhance citizen satisfaction of quality of life. This report explores Broader Asia’s strengths and weaknesses through country-level assessments of growth and innovation initiatives and benchmarks each country on these t...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and autoimmune disorders, metabolic and age-related conditions, neurodegenerative and neuromu...

The US and European mammalian contract development and manufacturing organization (CDMO) market is entering a new phase of strategic evolution, driven by accelerating biologics outsourcing, increasing molecule complexity, and growing demand for resilient, end-to-end manufacturing partnerships. As monoclonal antibodies, bispecific antibodies, Fc-fus...

Although the telecoms landscape in APAC has changed a lot since the onset of the COVID-19 pandemic, data as a key driver of traffic and 5G monetization as the industry’s biggest bottleneck remain important trends impacting the industry. As 5G enterprise develops, enhanced mobile broadband (eMBB) is expected to continue to impact the mobile operator...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping diagnostics, therapeutics, and clinical workflows across infectious diseases, women’s health, metabolic disorders, neurodegeneration, oncology, rare diseases, and musculoskeletal care. It hi...

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) ma...

AI generative design technology is emerging as a transformative tool across various industries, including the automotive sector. The technology tool presents tremendous potential for innovation in automotive design by enabling OEMs to explore multiple design iterations swiftly and cost-effectively to produce more fuel-efficient, lightweight vehicle...

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report ...